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A long-acting depot formulation of olanzapine that sustains plasma olanzapine concentrations for over a month after a single injection is
currently under development. This multicenter, open-label study explored D2 receptor occupancy of a fixed dose of olanzapine pamoate
(OP) depot given every 4 weeks. Patients (nine male, five female) with schizophrenia or schizoaffective disorder previously stabilized on
oral olanzapine were switched to OP depot 300 mg by intramuscular injection every 4 weeks for 6 months. No visitwise within-group
significant changes were found in Brief Psychiatric Rating Scale Total or Clinical Global Impressions-Severity of Illness scores, although
seven patients received oral olanzapine supplementation during the first four injection cycles. To minimize impact on D2 occupancy,
positron emission tomography (PET) scans were not completed during injection cycles that required supplemental oral olanzapine. Two
patients reported transient injection site adverse events, which did not result in discontinuation. The most frequently reported treatment-
emergent adverse events were insomnia, aggravated psychosis, and anxiety. Mean striatal D2 receptor occupancy, as measured by [
11C]-
raclopride PET, was 69% on oral olanzapine (5–20 mg/day) and 50% (trough) on OP depot at steady state. Following an initial decline,
occupancy returned to 84% of baseline oral olanzapine occupancy after six injections. Over the study period, D2 receptor occupancy and
plasma olanzapine concentrations were significantly correlated (r¼ 0.76, Pp0.001). OP depot resulted in mean D2 receptor occupancy
of approximately 60% or higher at the end of the 6-month study period, a level consistent with antipsychotic efficacy and found during
treatment with oral olanzapine. However, supplemental oral olanzapine or another dosing strategy may be necessary to maintain
adequate therapeutic response during the first few injection cycles.
Neuropsychopharmacology (2008) 33, 298–304; doi:10.1038/sj.npp.1301409; published online 18 April 2007
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INTRODUCTION
Patients with schizophrenia often discontinue their anti-
psychotic medications despite the high efficacy of these
drugs (Lieberman et al, 2005). Non-adherence to antipsy-
chotic medications is a primary reason for psychotic relapse
and rehospitalization (Perkins, 2002). Long-acting depot
antipsychotic agents may improve long-term outcomes,
especially among patients who frequently forget to take
their medications or refuse treatment because of lack of
insight. However, currently only one second-generation
antipsychotic agent, risperidone, has a depot formulation
available, and it must be administered once every 2 weeks
(Gefvert et al, 2005; Kane et al, 2003; Remington et al, 2006).
For most antipsychotic drugs, a striatal dopamine D2
receptor occupancy of X60% has been associated with
therapeutic response in patients with schizophrenia (Kapur
et al, 2000). This has led to the use of positron emission
tomography (PET) to complement pharmacokinetic and
dose–response clinical studies, to determine clinically
effective doses and dosing intervals of oral and depot
antipsychotic drugs (Mamo et al, 2004; Remington
et al, 2006). Oral olanzapine, a second-generation anti-
psychotic agent, has shown dose-dependent striatal D2
receptor occupancy of 60–80% at usual clinical doses
(10–20 mg/day) (Kapur et al, 1998). A long-acting depot
formulation of olanzapine is currently under development,
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and pharmacokinetic data from initial clinical studies using
this new formulation support a dosing interval of 2–4 weeks
(data on file, Eli Lilly and Company). In an effort to
complement these pharmacokinetic data with central in
vivo occupancy studies, this open-label PET study was
conducted using 300 mg olanzapine pamoate (OP) depot
administered by intramuscular injection to patients with
schizophrenia or schizoaffective disorder. Our primary
objective was to determine whether D2 receptor occupancy
was sustained for 4 weeks following injection of OP depot,
to ascertain the feasibility of administering this formulation
once every 4 weeks. Therefore, OP depot was given at
4-week dosing intervals for 6 months. Secondary objectives
were to assess the efficacy and safety of this regimen of OP
depot.
PATIENTS AND METHODS
Participants
Fourteen participants (nine male, five female) in this three-
center (Toronto, ON, Canada; Pittsburgh, PA, USA; New
York, NY, USA), open-label study (study code: F1D-EW-
HGJW) were inpatients or outpatients, aged 18–50 years,
who were diagnosed with DSM-IV schizophrenia or
schizoaffective disorder, and who were stable on oral
olanzapine treatment for the 4 weeks before study entry.
Patients with a history of serious, unstable medical illnesses,
who were pregnant or nursing at the time of the study, or
had received depot antipsychotic within 6 months of study
entry, were excluded. The study was approved by the
respective local research ethics boards, and participants
entered the study after signing an informed consent.
Study Design
After a 1-week ‘lead-in’ period, in which participants
continued to receive their prescribed dose of oral olanza-
pine (5–20 mg/day), baseline procedures (including plasma
olanzapine concentrations and an [11C]-raclopride PET
scan proximal to trough plasma concentrations) were
completed. Patients then received one intramuscular injec-
tion of 300 mg OP depot every 4 weeks for the duration of
the study period (6 months), with the total of six injection
cycles. Supplementation with oral olanzapine (5–20 mg/day)
was permitted to control any worsening of clinical status, as
assessed by the investigator, but not during the 4-week
injection cycle in which the patient received a PET scan.
Benzodiazepines (o40 mg diazepam equivalents/day),
benztropine mesylate (o6 mg/day), and anticholinergic
were permitted during the study.
Determination of Plasma Olanzapine Concentrations
Sparse venous blood samples (5 ml) were taken from each
patient at baseline (Week 0) and at various times
throughout the study period including pre-injection troughs
(at Week 4 of each cycle). Plasma olanzapine concentrations
were estimated from heparinized plasma using high-
performance liquid chromatography with electrochemical
detection (HPLC-EC; BAS Analytics, West Lafayette, IN).
Positron Emission Tomography
To determine D2 receptor occupancy of olanzapine in vivo,
an [11C]-raclopride PET scan of the striatum was performed
at baseline (Week 0) plus not more than three of the
following time points: 4, 8, 12, 16, 20, and 24 weeks before
administration of the next depot injection. PET imaging was
completed using standard protocols for [11C]-raclopride
PET at the three respective sites. The PET scans after the
first injection interval performed 4 weeks after the injection
of OP depot reflect trough D2 occupancy levels for the
interval before receiving the next injection of OP depot. The
majority of the patients in this study were recruited and
scanned at the Toronto site, the PET Centre of the Centre
for Addiction & Mental Health (8/14 patients), thus the
methods described below refer to the Toronto protocol. The
numbers of patients at the Pittsburgh and New York sites
were 4 and 2, respectively.
Three hundred seventy MBq of [11C]-raclopride (specific
activity 411 100 Bq/mmol) were injected intravenously
(bolus) and image acquisition was begun simultaneously.
PET scanning was conducted with a 15-slice (8-ring) brain
PET scanner (GEMS PC2048-Plus; General Electric Medical
Systems, Milwaukee, WI) using the non-wobble acquisition
mode. After a 10-min transmission scan for attenuation
correction of the emission scans, emission scans were
obtained every 1 min for the first 10 min, and then every
5 min for a total of 90 min. Scans were obtained while the
patient was in the supine position with the head fixed using
a thermoplastic face mask (Tru-Scan Imaging, Annapolis,
MD), which allowed for repositioning between procedures.
To permit accurate delineation of the brain regions for data
analysis, each patient had a magnetic resonance image
(MRI) scan carried out on a General Electric (GE)-Signal 1.5
Tesla scanner (GE LCC 9.4; General Electric Medical
Systems, Milwaukee, WI). The image was acquired using
two sequences: a conventional spin-echo pulse sequence
(slice thickness, 3 mm), and a high-resolution gradient-echo
pulse sequence (SPGR; slice thickness, 1.5 mm). PET and
MRI images were then co-registered using Review 8.0
software to use the MRI for delineating regions of interest
(ROIs) (Studholme et al, 1997).
ROIs used were the caudate and putamen, with the
cerebellum used as a reference region. The ROI analysis was
completed using Alice 3.1 (Perceptive Systems, Boulder,
CO), which allows the rater to draw ROIs on summed PET
images (representing averaged images of the dynamic time
series). The ROIs were drawn by a single rater on two axial
slices for the cerebellum (around the outermost border of
cerebellar cortex), and two axial slices for the striatum. The
ROIs were drawn such that their volume was larger than
twice the full-width at half-maximum to minimize errors
owing to partial volume effects (Volkow et al, 1993). The
ROIs were then transferred to the dynamic PET images
using the same software, and a time activity curve was
generated and used in the analysis.
D2-receptor binding potential (BP) was calculated using
previously described methods (Mamo et al, 2004). An
average of the striatum/cerebellum ratio minus one
obtained between 30 and 75 min of scanning was taken as
a measure of the equilibrium BP (Farde et al, 1986). This
timing was chosen because it has been shown that the ratio
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remains stable during this period, shows a very high
correlation (r40.95) with analytically derived estimates of
D2 BP (Kapur et al, 1996), is highly reliable with a scan–
rescan standard deviation of 6%, and has been standardized
with a high intra- and inter-rater reliability (intra-class
correlation coefficients: r40.95) (Kapur et al, 1998).
Receptor occupancy for a given dose was then calculated
as the percentage reduction of receptor BP with the
drug treatment compared with unmedicated baseline
(100 (1(BPdrug scan/BPunmedicated baseline))). To ensure
internal consistency, site-specific age-corrected measures
of BP were obtained from a previously collected data set of
antipsychotic-free healthy subjects. The data from these
patients were analyzed by the same rater to ensure within-
study consistency. The absence of the patients’ own
unmedicated baseline values introduces a potential error:
for D2-receptor occupancy this error, as calculated on the
basis of variance in the data from antipsychotic-naı¨ve
patients, is expected to vary from 0 to 9% for patients with
50% occupancy and 0–4% for patients who have 80%
occupancy.
Psychiatric and Tolerability Assessments
Psychiatric stability was evaluated every 2 weeks using
mean change from baseline to end point and visitwise
scores on the Brief Psychiatric Rating Scale (BPRS;
Overall, 1972) Total and the Clinical Global Impressions-
Severity of Illness (CGI-S; Guy, 1976) scale. Tolerability
was evaluated by monitoring for injection site reactions,
treatment-emergent adverse events, and baseline-to-end
point changes in vital signs (eg, blood pressure and
ECGs) and weight. Severity of the extrapyramidal
symptoms, parkinsonism and akathisia, were measured
using the Simpson–Angus Scale and Barnes Akathisia Scale,
respectively.
Statistical Analyses
Bivariate correlation analysis was used to examine the
relationship between the primary variables of interest.
Nonlinear regression analysis was used to evaluate the
relationship between plasma olanzapine concentration and
receptor occupancy (SPSS Inc., Chicago, IL) using the
following equation: occupancy¼ Emax (plasma concentra-
tion/(plasma concentration + EC50)), where Emax is the
maximum receptor occupancy and EC50 is the estimated
plasma olanzapine concentration (ng/ml) associated with
50% maximal receptor occupancy. The plasma olanzapine
concentration associated with 50% receptor occupancy
(EC50) was determined.
For the BPRS Total and CGI-S mean changes, within-
group t-tests were performed at each visit to test whether
any of the changes were significantly different from zero.
Baseline-to-end point changes on these scales were analyzed
using the last-observation-carried-forward, whereas visit-
wise changes were evaluated with the observed-cases
approach. Significant levels were set at Po0.05, with SAS
Version 8 used. Visitwise within group t-tests were used to
assess tolerability.
RESULTS
Baseline Characteristics and Disposition
Of the 20 patients who entered the study, six were excluded
because the protocol entry criteria were not met and one,
because of patient decision. Thus, 14 patients (five female)
were enrolled into the study and received at least one injection
of 300 mg OP depot. Their mean age (7SD) was 34.779.8
years, and the mean duration of illness (7SD) was 13.5710.6
years. Half of the study sample were cigarette smokers. All
patients were on oral olanzapine for a minimum of 4 weeks
before study entry and the dose of their medication had not
changed for at least 2 weeks before entry in study. Three
patients discontinued, one each owing to the following: an
adverse event (Week 16, seizure secondary to water intoxica-
tion in patient with historical diagnosis of epilepsy), patient
decision (Week 8, personal decision), and physician decision
(Week 4, continuous elevated creatine kinase (CK) laboratory
values, the patient had a history of CK elevation with previous
antipsychotic medication). Data for these patients were
included up to the point of discontinuation.
Plasma Olanzapine Concentrations
At baseline, after the administration of oral olanzapine
doses of 7.5, 10, 12.5, 15, and 20 mg, mean plasma
olanzapine concentrations were 7.4, 22.3, 31.2, 18.6, and
67.9 ng/ml, respectively. Mean plasma olanzapine concen-
tration across these doses was 37.4731.2 ng/ml (range:
6.14–116.09 ng/ml; n¼ 13, baseline data not available for
one patient) with an average daily oral olanzapine dose at
baseline of approximately 15 mg/day vs a mean OP depot
dose of 10.7 mg/day. There was large individual variability
in mean steady-state exposure. Mean plasma olanzapine
concentrations initially declined, then appeared to reach
steady-state by approximately Week 8, as suggested by the
similarity of mean concentrations after this time through
the duration of the study (Table 1). The mean exposure at
steady-state after the administration of 300 mg/4 weeks OP
depot was 20.3711.2 ng/ml.
D2 Receptor Occupancy
All patients received a PET scan at baseline, although each
patient could only receive four PET scans in total during the
study. To minimize the effect of oral supplementation on the
PET data, PET scans were not completed in OP depot dosing
cycles that required oral supplementation. Two patients
received scans at Week 1, five patients at Week 2, four at
Week 3, and six at Week 4. Four patients received scans 4 weeks
after the second (Week 8), third (Week 12), fourth (Week 16),
fifth (Week 20), and sixth (Week 24) injections of depot.
The mean D2 occupancy at baseline was 69.1715.2%
(n¼ 14), reflecting the occupancy of the oral olanzapine
dose of the study group (15.274.8 mg/day). Over the entire
study period, an expected curvilinear asymptotic significant
relationship was found between plasma olanzapine con-
centrations and D2 receptor occupancy (r¼ 0.76, Pp0.001)
(Figure 1). These data were fitted to the equation described
in the Patients and Methods section to yield a concentration
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associated with 50% of maximal occupancy (EC50) of
11.071.3 ng/ml (mean7SE). The EC50 was estimated after
pooling the data across investigator sites because no notable
differences in parameter estimates were obtained when the
data from each of the sites were fitted separately.
During the first injection cycle, D2 receptor occupancy
declined to approximately 70% of baseline values (occu-
pancy change, mean7SD, %: 21.0715.0) (Table 1; Figure 2),
consistent with mean plasma olanzapine concentrations
after the first OP depot dose being lower than the steady-
state range of oral olanzapine concentrations. Beyond the
second injection cycle, a gradual increase was observed in
mean D2 occupancy, paralleling the accumulation of
systemic olanzapine exposure, which reached a mean of
60% in the final two injection cycles. Thus, by the fifth
injection cycle, the D2 occupancy returned to 84% of the
baseline occupancy level on oral olanzapine.
Psychiatric Stability
Mean (7SD) change from baseline to end point (Week 24)
was 2.379.5 on the BPRS Total and 0.0771.21 on the
CGI-S, none of which were statistically significant.
At baseline, mean (7SD) scores were 9.178.1 for the
BPRS Total and 2.770.8 for the CGI-S. Upon visual
inspection, the visitwise (biweekly) mean change scores
on the BPRS Total showed some symptomatic worsening
during the first 6 weeks of the study (1.4 points at 6 weeks;
Figure 3); however, none of these changes were significantly
different from zero. Visitwise mean change scores on the
CGI-S were also not significantly different from zero (data
not shown). It is worth emphasizing that the absence of
change, as measured by the BPRS Total and the CGI-S,
might reflect a contribution of supplemental oral olanzapine
to the depot medication on an as needed basis during the
first four injection cycles (described below).
Seven patients (18 total instances), in the opinion of the
investigator, required supplemental oral olanzapine to
address early signs of clinical deterioration. The need for
supplemental oral olanzapine was generally restricted to the
first three injection cycles (with the exception of two
instances of oral supplementation in the fourth injection
cycle). Of note, in two of these patients, oral olanzapine
dosage was decreased approximately 25% within 3 weeks of
study entry.
Table 1 D2 Receptor Occupancy and Plasma Olanzapine Concentrations Following Administration of 300 mg Olanzapine Pamoate (OP)
depot Injections Every 4 Weeks for 6 Months
D2 receptor occupancy (%) Plasma olanzapine concentration (ng/ml)
Injection cycle Study week N Mean7SD N Mean7SD
Baseline 0a,b 14 69.1715.2 13 37.4731.2
1 1 2 52.575.0 4 10.174.4
2 5 52.6713.0 13 14.479.9
3 4 57.075.7 7 12.876.7
4b 6 48.1713.0 14 14.078.0
2 6 0 F 1 40.2
8b 4 46.578.9 13 26.5719.2
3 10 0 F 2 26.5712.9
12b 4 53.079.5 12 28.6720.8
4 16b 4 54.0718.7 12 21.8716.7
5 20 4 60.2717.1 11 20.5713.0
6 24b 4 61.5715.5 11 20.4711.2
Total 51 57.9714.9 113 22.0718.0
F¼ not applicable; N¼ number of measurements.
aWeek 0 measurements correspond with oral olanzapine dosing.
bInjection of OP depot administered; measurements were taken before the injection.
Figure 1 Percent D2 receptor occupancy as a function of plasma
olanzapine concentrations at 4 Weeks after Injection of 300 mg OP Depot
(N¼ 14). The regression line has been fit to the rectangular hyperbole
equation: occupancy¼ Emax (plasma concentration/(plasma concentra-
tion + EC50)), where Emax is the maximum receptor occupancy with an
estimated EC50 (7SD)¼ 11.071.3 ng/ml.
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Tolerability
Insomnia, aggravated psychosis, and anxiety were the most
frequently reported treatment-emergent adverse events
(n¼ 5 patients each). Dizziness and increased weight were
spontaneously reported by three patients each. One patient
reported an injection site granuloma, and another patient
reported injection site induration, pain, and swelling. These
injection site reactions were transient and did not result in
discontinuation. Despite the fact that the patients had been
stabilized on oral olanzapine for a minimum of 4 weeks
before study entry, there was still a small net baseline-
to-end point increase in weight (mean (7SD) 0.4073.8 kg
(NS)), with two patients reporting X7% increase from
baseline (one had received oral olanzapine for 416 days
before study entry, and the other 37 days). Two patients
experienced a significant decrease (3–31 mm Hg and
6–34 mm Hg) in orthostatic systolic blood pressure, and one
Figure 2 Mean D2 receptor occupancy over the 6-month study period (N¼ 14). OP depot injections (300 mg) were given every 4 weeks. * Denotes
plasma olanzapine concentrations; m shows when injections were administered; n, number of PET scans.
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Figure 3 BPRS Total mean change over time (observed case). BPRS Total scores were collected biweekly. Mean changes were not significantly different
from zero at any time point. m Shows when injections were administered.
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patient experienced a potentially clinically significant
prolonged ECG QTc interval (Bazett’s; from 401 ms at
baseline to 454 ms at Week 24). Mean (7SD) baseline-
to-end point change on the Simpson–Angus Scale was
0.2171.63, and on the Barnes Akathisia Scale,
0.1470.53. One patient spontaneously reported akathisia
at Week 12 (during the third injection cycle).
DISCUSSION
In this 6-month open-label study, we evaluated striatal
dopamine D2 receptor occupancy, plasma olanzapine
concentrations, and tolerability of 300 mg OP depot
administered every 4 weeks for 6 months in patients with
schizophrenia or schizoaffective disorder previously stabi-
lized on oral olanzapine. Depot injection of 300 mg every 4
weeks resulted in mean steady-state plasma olanzapine
concentrations of 20.3711.2 ng/ml among these non-
acutely ill patients, similar to the 23 ng/ml threshold that
predicted response among acutely ill patients with schizo-
phrenia treated with 2.5–17.5 mg/day oral olanzapine (Perry
et al, 2001). The mean daily oral olanzapine dose at baseline
was 15 mg, yielding a slightly higher mean plasma
concentration across this range of 37.4731.2 ng/ml. Thus,
the slight discrepancy in steady-state plasma olanzapine
concentrations is understandable. Consistently, D2 occu-
pancy stabilized very close to baseline levels (mean
occupancy was approximately 60% at 6 months compared
with 70% at baseline). This reflects the asymptotic nonlinear
relationship that is known to exist between plasma
concentrations and D2 receptor occupancy with atypical
and typical antipsychotic drugs, including olanzapine
(Tauscher et al, 2002). These changes were mirrored by
seven patients receiving oral supplementation within the
first four injection cycles, suggesting central D2 occupancy
generally required for antipsychotic efficacy (Nordstro¨m
et al, 1993) was not attained in these patients until steady-
state plasma concentrations were reached. Overall, the
results of this study appear to support 4-week dosing
intervals for 300 mg of OP depot, although some oral
supplementation or alternative dosing strategy may be
necessary to maintain adequate therapeutic response during
the first few injections cycles. This slight drop in mean
steady-state exposure, compared with the mean oral base-
line concentration, is understandable given that the daily
dose delivered by depot injection of 300 mg/4 weeks was
approximately 10 mg/day.
During the first four injection cycles, seven patients
received supplementation with oral olanzapine, although all
patients were able to taper dosing within three injection
cycles. No patients received oral supplementation at the
time of PET scanning; thus, the occupancy data would not
have been influenced. This supplemental dosing reflects
physician-noted clinical deterioration, paralleling the trend
toward general worsening on the BPRS Total within the first
two injection cycles. This transient clinical deterioration
could have been related to the initial decline in central D2
receptor occupancy, which was resolved by the increase in
occupancy owing to supplementation. Oral olanzapine
supplementation diminished when occupancy with OP
depot treatment reached X60% steady-state plasma
concentrations during the fourth injection cycle. These
data suggest that, although the 4-week dosing strategy was
adequate beyond the first four injection cycles, a dose of
300 mg OP depot every 4 weeks alone may be less than
optimal for maintaining therapeutic response in patients
stabilized on oral olanzapine. Thus, oral supplementation in
the first three injection cycles may be necessary to maintain
therapeutic response at the dose and dosing interval used in
this study. Alternative strategies to address the decreased
central occupancy during the first four injection cycles may
include the administration of higher doses (eg, 400 mg/4
weeks) or increasing the frequency of depot dosing for
the first three months (eg, giving the OP depot once every
2 weeks).
While this study is limited by the small number of
patients compounded by sparse sampling across
time (owing to the limit of four PET scans per patient),
the use of a fixed dose within an open-label design, and
the lack of active or placebo comparator, we do not believe
that these limitations detract from the conclusions drawn.
This study was completed in three different sites, introdu-
cing the possibility of inconsistent PET scanning acquisition
methodology across the respective study sites. To address
this, we estimated the olanzapine plasma concentration
that would be expected to result in 50% occupancy (EC50)
across the respective sites and found no appreciable
differences between sites, suggesting that our results
were not influenced by location. It should also be pointed
out that because there were many more pharmaco-
kinetics samples than D2 receptor scans, the plasma
concentration and D2 occupancy data obtained at any given
time point do not necessarily represent the same popula-
tion. Finally, the conclusions drawn are only applicable
to individuals who are stabilized on oral olanzapine for
a minimum of 4 weeks before commencing OP depot
treatment.
As this study involved a change in medication, it would
have been ethically unreasonable not to allow for the use of
anticholinergics and benzodiazepines on an as needed basis.
It has previously been reported that lorazepam increases the
BP of [11C]-raclopride in anesthetized baboons beyond test–
retest values, a finding thought to be related to the release of
endogenous dopamine (Dewey et al, 1992). Hence, in the
current study, the occupancy results for patients receiving
benzodiazepines may have been underestimated to a small
degree. Similarly, it has previously been reported that
scopolamine decreases the BP in healthy human volunteers
(Dewey et al, 1993), giving rise to the possibility of
over-estimation of occupancy for patients receiving anti-
cholinergics.
Conclusion
Although future controlled studies are needed to evaluate
the efficacy of dosing strategies, the results suggest that, in
patients with schizophrenia or schizoaffective disorder
previously stabilized on oral olanzapine for a minimum of
4 weeks, 300 mg OP depot administered intramuscularly
every 4 weeks may be sufficient for therapeutic levels of
central D2 receptor occupancy. However, our results also
suggest that some patients may need supplemental oral
olanzapine, at least within the first three injection cycles, to
maintain optimal therapeutic response. Nonetheless, by the
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end of 6 months of treatment with OP depot, D2 receptor
occupancy reached levels that are consistant with anti-
psychotic efficacy. Furthermore, both the D2 receptor
occupancy attained and the tolerability profile of OP depot
were consistent with those found during treatment with oral
olanzapine, and, importantly, injection site adverse events
were reported in only two patients and were transient and
did not result in study discontinuation.
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